# Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT02289898** · PHASE2 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 207 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Demcizumab
- **DRUG:** Abraxane®
- **DRUG:** gemcitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02289898
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-20
- **Primary completion:** 2017-05
- **Final completion:** 2017-09
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2020-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289898, "Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02289898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*